Biohaven could get up to $795M in epilepsy alliance with SK Bio

PartnershipopakalimPositive

AI Analysis

Summary

Biohaven entered an alliance with SK Biopharmaceutical worth up to $795M centered on the ion channel platform and lead epilepsy candidate opakalim, with Phase 2/3 data expected later in 2026.

Clinical Trial Data

Phase

2/3

Outcome Details

Biohaven alliance with SK Biopharmaceutical for ion channel platform and opakalim development; potential $795M deal value

Importance:7/10

Sentiment:

0.70

partnershipallianceepilepsyPhase 2/3ion channel platformSK Bioopakalim

Related Companies

$BHVN

Read the original article

Published by BioSpace on August 26, 2026 12:14 PM

Read Original